This report pulls together key findings from the OM1™ Real-World Data Cloud and some of OM1’s clinical registries.
The report covers examples of applications for real-world data and machine learning in evaluating real-world outcomes and is broken into four chapters:
Rheumatoid Arthritis
- Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice
- Patient Reported Outcomes and Changes in DMARD Therapy for Rheumatoid Arthritis in Routine Clinical Practice
Giant Cell Arteritis
- Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis)
Systemic Lupus Erythematosus
- Availability of Disease Activity Measures from Systemic Lupus Erythematosus Patients in a Large, Representative US-Based Real World Registry Cohort
- Patient Characteristics and Current Management of Systemic Lupus Erythematosus Patients in a Large, Representative US-based Real World Registry Cohort
Juvenile Idiopathic Arthritis
- Patient Characteristics and Management of Juvenile Idiopathic Arthritis (JIA) in a Large, Representative Real World Cohort
